01530 3SBIO
- 6.590
- 0.0000.00%
3SBIO News
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
三生製藥：2023 年度報告
Sansheng Pharmaceutical (01530.HK) was granted an additional 982,400 shares of common stock by Lou Jing, worth approximately HK$7.502 million
On April 24, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 24, 2023, Lou Jing increased his common stock holdings of $Sansheng Pharmaceutical (01530.HK) by $982,400 at an average price of HK$7.6365 per share, worth about HK$7.502 million. After the increase in holdings, Lou Jing's latest shareholding was 528 million shares, and the good position ratio increased from 21.63% to 21.67%. Additional Information: Dr. Lou Jing is an enforcer and a benefit of an unname
Repurchase Collection on April 22 | HSBC Holdings, Hang Seng Bank, etc. bought back one after another, of which HSBC Holdings spent HK$78.0367 million
According to HKEx's April 23 disclosure documents, $HSBC Holdings (00005.HK) $ and $Hang Seng Bank (00011.HK) $ repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 1,266,800 common shares on April 19, involving an amount of HK$78.367 million. The repurchase price per share ranged from HK$62 to HK$61.25. ② $Hang Seng Bank (00011.HK) $ repurchased 600,000 common shares on April 22, involving an amount of HK$58.405 million. The repurchase price per share ranged from HK$98.7 to HK$9
Sansheng Pharmaceutical (01530.HK): Zhang Dan intends to retire as an independent non-executive director
Gelonghui, April 22 | Sansheng Pharmaceutical (01530.HK) announced that Zhang Dan, an independent non-executive director, will step down in rotation at the company's annual general meeting of shareholders to be held on June 25, 2024. Independent non-executive director Wong Cho-yiu has been appointed by the board of directors as a member of the Remuneration Committee, effective immediately after the 2023 Annual General Meeting of Shareholders to be held on June 25, 2024.
Sansheng Pharmaceutical (01530): Wong Cho-yiu appointed as a member of the Remuneration Committee
Sansheng Pharmaceutical (01530) issued an announcement. According to the company's articles of association, Zhang Dan, an independent non-executive director, will...
Sansheng Pharmaceutical (01530.HK) spent HK$838,900 to buy back 150,000 shares on April 22
Gelonghui, April 22丨Sansheng Pharmaceutical (01530.HK) announced that it spent HK$838,900 to repurchase 150,000 shares on April 22.
Repurchase Collection on April 16 | HSBC Holdings, Changshi Group, etc. bought back one after another, of which HSBC Holdings spent HK$206 million
According to documents disclosed by the Hong Kong Stock Exchange on April 17, $HSBC Holdings (00005.HK) $, $Changshi Group (01113.HK) $, etc. repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 3.2412 million common shares on April 15, involving an amount of HK$206 million. The repurchase price per share ranged from HK$63.85 to HK$63.1. ② $Changshi Group (01113.HK) $ repurchased 2,434,500 common shares on April 16, involving an amount of HK$76.3271 million, with a repurchase price of HK$31.4 per share
Sansheng Pharmaceutical (01530.HK) spent HK$20.315 million to buy back 3.537 million shares on April 16
Gelonghui announced on April 16: Sansheng Pharmaceutical (01530.HK) announced that it spent HK$20.315 million to repurchase 3,537 million shares on April 16.
Repurchase Collection on April 15 | HSBC Holdings, Hang Seng Bank, etc. bought back one after another, of which HSBC Holdings spent HK$263 million
According to HKEx's April 16 disclosure documents, $HSBC Holdings (00005.HK) $ and $Hang Seng Bank (00011.HK) $ repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 4.147,200 common shares on April 12, involving an amount of HK$263 million. The repurchase price per share ranged from HK$63.85 to HK$63.05. ② $Hang Seng Bank (00011.HK) $ repurchased 5992 thousand common shares on April 15, involving an amount of HK$58.728 million, with a repurchase price of HK$99.3 per share
Sansheng Pharmaceutical (01530.HK) spent HK$15.598 million to repurchase 2,649,500 shares on April 15
Gelonghui, April 15 | Sansheng Pharmaceutical (01530.HK) announced that it spent HK$15.598 million to repurchase 2,649,500 shares on April 15.
3SBIO Gets China Nod for Use of Cancer Injection in Children With Thrombocytopenia
3SBIO (HKG:1530) said the National Medical Products Administration of China approved its Recombinant Human Thrombopoietin Injection for the treatment of persistent or chronic primary immune thrombocyt
Repurchase Collection on April 12 | Tencent Holdings, HSBC Holdings, etc. have repurchased, of which Tencent Holdings spent HK$1 billion
According to documents disclosed by the Hong Kong Stock Exchange on April 15, $Tencent Holdings (00700.HK) $ and $HSBC Holdings (00005.HK) $ repurchased shares. ① $Tencent Holdings (00700.HK) $ repurchased 3.2 million common shares on April 12, involving an amount of HK$1 billion. The repurchase price per share ranged from HK$317.4 to HK$309.4. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 212 million shares, accounting for 2.211% of the number of shares issued when the ordinary resolution was passed. ② $HSBC Holdings (0000
Sansheng Pharmaceutical (01530.HK) Recombinant Human Thrombocytopoietin Injection (Terbiao) Approved for ITP Indications for Children
Gelonghui, April 12, 丨 Sansheng Pharmaceutical (01530.HK) announced that the new indications for Sansheng Pharmaceutical's recombinant human thrombocytopenia injection (Terbiao) submitted by the company to the National Drug Administration (NMPA) were approved on April 2 to treat persistent or chronic primary immune thrombocytopenia (ITP) in children or adolescents. Terbiao is a recombinant human thrombopoietin (rHTPO) injection independently developed by Sansheng Pharmaceutical. It has previously been approved for adult solid tumors after chemotherapy
Sansheng Pharmaceutical (01530.HK) spent HK$10.39 million to buy back 1.746 million shares on April 12
Gelonghui, April 12, 丨 Sansheng Pharmaceutical (01530.HK) issued an announcement. On April 12, 2024, it spent HK$10.39 million to repurchase 1.746 million shares at a repurchase price of HK$5.93-5.98 per share.
Repurchase Collection on April 11 | Tencent Holdings, HSBC Holdings, etc. have repurchased, of which Tencent Holdings spent HK$1 billion
According to documents disclosed by the Hong Kong Stock Exchange on April 12, $Tencent Holdings (00700.HK) $ and $HSBC Holdings (00005.HK) $ repurchased shares. ① $Tencent Holdings (00700.HK) $ repurchased 3.18 million common shares on April 11, involving an amount of HK$1 billion. The repurchase price per share ranged from HK$316.6 to HK$311.2. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 209 million shares, accounting for 2.178% of the number of shares issued when the ordinary resolution was passed. ② $HSBC Holdings (0000
Featured announcements | Shandong Gold's Q1 net profit is expected to increase by 48.11% to 70.9% year-on-year
Xinji Shaxi: 14.16% of the company's shares held by the controlling shareholder were forcibly sold, and trading resumed today; express sales: net profit of 195.9 billion yen in the first half of the year, up 27.7% year on year; Smore International: profit after tax for the first quarter was about 339.5 million yuan, up 12.8% year on year.
Sansheng Pharmaceutical (01530.HK): Approval of ITP indications for children in Terbi Australia is expected to support continued income growth
Incident On April 11, 2024, the company announced that a new indication for recombinant human thrombocytopenia injection (terbiao) was approved on April 2 to treat persistent or chronic primary immune thrombocytopenia in children or adolescents
Sansheng Pharmaceutical (01530.HK) spent HK$16.7497 million to repurchase 2.805 million shares on April 11
Sansheng Pharmaceutical (01530.HK) announced that on April 11, 2024, the company spent HK$16.7497 million to repurchase 2.805 million shares at a repurchase price of HK$5.92-6.04 per share.
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Analysis
Price Target
No Data
